Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation (AKP) recently announced they have entered into a long-term strategic collaboration for the development, commercialization, and supply of a weekly transdermal patch formulation of Teribone (teriparatide acetate), AKP's formulation of human parathyroid hormone (human PTH 1-34), for the treatment of osteoporosis patients with a high risk of fracture. Under the terms of the agreement, AKP has received exclusive rights to develop and commercialize the transdermal patch formulation of Teribone in Japan, Korea, China, and Taiwan. AKP is responsible for clinical and regulatory development and commercialization activities.